Header

UZH-Logo

Maintenance Infos

The MT2 melatonin receptor subtype is present in human retina and decreases in Alzheimer's disease


Savaskan, E; Jockers, R; Ayoub, M; Angeloni, D; Fraschini, F; Flammer, J; Eckert, A; Müller-Spahn, F; Meyer, P (2007). The MT2 melatonin receptor subtype is present in human retina and decreases in Alzheimer's disease. Current Alzheimer Research, 4(1):47-51.

Abstract

The pineal and retinal melatonin regulates endogenous circadian rhythms, and has various physiological functions including neuromodulatory and vasoactive actions, antioxidative and neuroprotective properties. We have previously demonstrated that the melatonin 1a-receptor (MT(1)) is localized in human retinal cells and that the expression of MT(1) is increased in Alzheimer's disease (AD) patients. We now present the first immunohistochemical evidence for the cellular distribution of the second melatonin receptor, MT(2), in the human retina and in AD patients. In elderly controls, MT(2) was localized to ganglion and bipolar cells in the inner nuclear layer, and to the inner segments of the photoreceptor cells. In addition, cellular processes in inner and outer plexiform layers were strongly positive for MT(2). In AD patients the overall intensity of MT(2)-staining was distinctly decreased in all observed cellular localizations. Our results indicate that MT(2) in the humans, similar to MT(1), may indeed be involved in transmitting melatonin's effects in the retina, and AD pathology may impair MT(2) expression. Since our previous results showed an increase in MT(1) expression in AD retina, the two melatonin receptor subtypes appear to be differentially affected by the course of the neurodegenerative disorder.

Abstract

The pineal and retinal melatonin regulates endogenous circadian rhythms, and has various physiological functions including neuromodulatory and vasoactive actions, antioxidative and neuroprotective properties. We have previously demonstrated that the melatonin 1a-receptor (MT(1)) is localized in human retinal cells and that the expression of MT(1) is increased in Alzheimer's disease (AD) patients. We now present the first immunohistochemical evidence for the cellular distribution of the second melatonin receptor, MT(2), in the human retina and in AD patients. In elderly controls, MT(2) was localized to ganglion and bipolar cells in the inner nuclear layer, and to the inner segments of the photoreceptor cells. In addition, cellular processes in inner and outer plexiform layers were strongly positive for MT(2). In AD patients the overall intensity of MT(2)-staining was distinctly decreased in all observed cellular localizations. Our results indicate that MT(2) in the humans, similar to MT(1), may indeed be involved in transmitting melatonin's effects in the retina, and AD pathology may impair MT(2) expression. Since our previous results showed an increase in MT(1) expression in AD retina, the two melatonin receptor subtypes appear to be differentially affected by the course of the neurodegenerative disorder.

Statistics

Citations

Dimensions.ai Metrics
58 citations in Web of Science®
63 citations in Scopus®
Google Scholar™

Altmetrics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > Institute for Regenerative Medicine (IREM)
Dewey Decimal Classification:610 Medicine & health
Scopus Subject Areas:Life Sciences > Neurology
Health Sciences > Neurology (clinical)
Language:English
Date:2007
Deposited On:06 Sep 2011 09:07
Last Modified:23 Jan 2022 19:09
Publisher:Bentham Science
ISSN:1567-2050
OA Status:Closed
Publisher DOI:https://doi.org/10.2174/156720507779939823
PubMed ID:17316165
Full text not available from this repository.